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ABSTRACT
Background: Sub-Saharan Africa with under 10% of the world’s total population 
accounts for 60-70% of all HIV/AIDS cases. While these patients require HAART to 
manage the disease, HAART is not universally available. Majority of the patients are in 
resource-constrained settings, have multiple co- morbidities/infections, opportunistic 
infections, present late for treatment and are in the advanced stages of the HIV/A±IDS 
infection.
Objective: To describe the CD4+ cell counts, opportunistic infections and laboratory 
parameters of a cohort of HIV positive, HAART-naïve patients at first presentation.
Design: Cross sectional, prospective, descriptive, consecutive entry study.
Setting: Kisumu District Hospital wards (medical, surgical) and medical outpatient 
clinic, Nairobi Rheumatology Clinic, Nairobi West Hospital and the Mater Hospital 
between January 2001 and December 2008.
Main outcome measures: Socio-demographic parameters, opportunistic infections, 
CD4+ cell counts and complete blood count, biochemistry, HBsAg markers and anti-
HCV serostatus.
Results: Eight hundred and thirty four (350 males and 484 females) patients were 
screened. Three hundred and seventy (94 males and 276 females) patients were 
excluded. Four hundred and sixty four (256 males and 208 females) patients were 
finally included in the study. The mean age was 37.2 ±10.6 years, range (12-78). The 
M: F ratio was 1.2:1. The mean CD4+ cell count was 106.5 ± 125.2 cells/µl manifesting 
severe immnosuppression.  Fifteen (3.2%), 19(4.1%), 43(9.3%) and 387(83.5%) had CD4+ 
cell counts of > 500, 350-499, 200-349 and < 200 cells/µl respectively. The mean white 
blood cell count was 8.63 ± 8.8 × 103/ml (4.8-10.8 × 103/µl). Over half (51.3%) patients 
had leucopaenia, white cell count < 4.8 × 103/µl, 35 (7.5%) had leucocytosis and the 
rest 191 (41.2%) patients had normal white blood cell counts. The mean haemoglobin 
level was 7.16 ± 5.01 g/dl (12-18 g/dl) and 154 (33.2%) had haemoglobin level < 5g/dl 
manifesting severe anaemia.  The patients had multiple co-morbidities and 248 (53.4%) 
had ≥ 2 co-morbidities. 
Conclusion: The patients presented with severe immunosuppression evidenced by 
low CD4+ cell counts, anaemia and multiple co-morbidities. Majority presented late 
at which point the cost of management is high and outcomes are likely to be poor. 
They required HAART and prompt management of the co-morbidities to mitigate 
morbidity and reduce mortality. It would be prudent to study treatment outcomes and 
their determinants overtime in patients with severe HIV disease. Also, requiring study 
is how long such patients with severe HIV disease who commence HAART would last 
on first line treatment before requirement of alternative treatment.
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INTRODUCTION
Today, over 38 million people are living with HIV/
AIDS infection globally, with five million new 
infections acquired annually (1,2). Sub-Saharan 
Africa, with under 10% of the world’s total population 
accounts for 60-70% of HIV/ AIDS cases worldwide. 
In Botswana, about 45% of pregnant women are 
infected. Kenya has an estimated national prevalence 
of 6.8% and approximately 1.1 million people living 
with AIDS (PLWAs) and still experiencing devastating 
effects of HIV/AIDS epidemic (3, 4). These patients 
require highly active anti-retroviral therapy (HAART) 
to manage the disease. It is noteworthy that Sub-
Saharan Africa has a population of 25.4 million people 
living with HIV/AIDS, 3.1 million new HIV/AIDS 
infection annually and experiences 2.3 million HIV/
AIDS related deaths annually (5).
 First diagnosed about 30 years ago, HIV/AIDS 
presents with multiple opportunistic infections and 
other co-morbidities especially in the advanced stages 
where HAART had not been initiated. Most patients 
in resource-constrained setting present late to patient 
support centres / comprehensive care clinics (PSCs/
CCCs) because of stigma, poor socio- economic status, 
inaccessibility to care in PSCs/CCCs for a variety of 
reasons. Lately the government has rolled out free 
HAART access in various parts of the country as a 
public health intervention programme.
 Few studies have been done locally to show 
the morbidity pattern and CD4+ cell count at initial 
presentation to the clinics. Indeed the management of 
opportunistic infections has a bearing on the choice 
of HAART and outcomes. 
 This study presents a cohort of HAART naïve, 
HIV positive patients whose clinical and laboratory 
parameters were analysed at the initial presentation 
to the clinics. This was at a time when there were few 
CCCS/PSCS countrywide. The patients were funding 
their own care, the ARTS and the medications for 
managing co-morbidities.
MATERIALS AND METHODS
Eight hundred and thirty four patients (350 males and 
484 females) were examined and screened.
Three hundred and seventy (94 males and 276 females) 
were excluded due to incomplete data and as a result, 
only 464 (256 males and 208 females) were included 
in the study. Informed, signed consent was obtained 
from each patient, (< 18 years old or in coma, signed 
by parent(s) or guardian). The ethics and standards 
committee of Kisumu District Hospital and hospital 
administration of the other hospitals, approved the 
study. A standard questionnaire was run for each 
study subject and it included: bio-data, symptoms 
and signs. Each patient underwent a thorough clinical 
examination by the clinicians. A DTC (diagnostic 
testing and counselling) was done to each previously 
undiagnosed patient and post-test counselling was 
sustained for all patients.  Twenty patients presented 
for care with a known HIV positive sero-status 
from a referral voluntary counselling and testing 
(VCT) centre. Under aseptic technique, blood was 
drawn from the cubital fossa and used to determine 
complete blood count, CD4+ cell count, and ELISA 
test for HIV and hepatitis B surface antigen (HBsAg), 
AST, ALT and anti-HCV antibodies. A clinical 
diagnosis was made for each patient who was then 
investigated and managed appropriately as an out- 
or in-patient. The CD4+ cell count was determined 
using fluorescent activated cell sorter (FACS) flow 
cytometry method with a sensitivity of 1-2000 cells/
μl (FACS count machine from Baxton, Dickson). 
Appropriate investigations (Laboratory, radiology) 
were undertaken to further evaluate/confirm the 
diagnosis (Table 1). Complete blood count was done 
using the Coulter counter machine. The liver function 
tests were analysed using the technicon RA 1000 
machine (Technicon  RA systems No. sm-0034 D91 
and sm4-0137, D 91, 1996). The results were expressed 
as mean ± SD, histograms and tables.
Intervention: The patients were seen for routine 
clinical care in the hospitals where the study was 
conducted. The opportunistic infections and other 
co-morbidities were managed appropriately. HAART 
was promptly initiated (within 7-29 days) in all the 
included patients.
 Twenty eight patients (17 females, 11 males) 
could not start HAART promptly due to the severe 
co-morbidities they had which had to be managed 
(10 had severe anaemia of haemoglobin < 5g/dl 
which required blood transfusion, 13 had hepatitis 
B virus infection and non-viral causes of elevation 
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of transaminases-AST and ALT and five had 
cryptococcous meningitis and were in coma). The 
patients survived and were subsequently followed 
up by the authors (MDs) as out patients. Follow 
up CD4+ cell counts were done every three to four 
months on average to assess response to HAART. 
The patients who had CD4+ cell counts < 100 cells/
μl were followed up every month or as need arose.
 Patients who could not afford HAART were 
referred to alternative HIV-CARE clinics available. 
ARTs - Stavudine/ Lamivudine/ Nevirapine or             
 Efavirenz.
      - Fixed dose combination-EMTRI 30/40 or  
 Triomune 30/40
RESULTS
Eight hundred and thirty four (350 males and 
484 females) were evaluated for the study. Three 
hundred and sixty six (90 males and 276 females) 
were excluded due to incomplete data (HIV positive 
but no data on CD4+ cell count and haematological 
parameters). Four hundred and sixty four (256 
males and 208 females) patients were included. 
The male: female ratio was 1.2:1. The mean age was 
37.2 ± 10.6 years (range 12-78). The mean CD4+ cell 
count was low, 106.5 ± 125.2 cells/μl, range of (0.4-
1022 cells/μl). Fifteen (3.2%), 19(4.1%) and 43(9.3%) 
patients had CD4+ cell counts > 500, 350-499 and 
200-349 cells/μl respectively. Three hundred 
and eighty seven (83.4%) patients had CD4+ 
cell count of  < 200 cells/μl manifesting severe 
immunosuppression.
 Two hundred and thirty eight (51.3%) patients 
had leucopenia with low white cell count < 4.8 × 103/
ml, 191 (41.2%) had normal white cell count of 4.8-10.8 
× 103/ml and 35 (7.5%) had leucocytosis (white cell 
count > 10.8 × 103/ml). Mean haemoglobin level was 
7.16 ± 5.01 g/dl. Eighteen (3.9%) patients, 50(10.8%) 
patients, 109(23.5%) patients, 127 (27.3%) patients 
and 160 (34.5%) patients had haemoglobin levels of 
> 10.6g/dl, 9.5-10.5 g/dl, 8.0-9.4 g/dl, 6.5-7.9g/dl 
and < 6.5g/dl respectively
 Thus, 160 (34.5%) patients had severe anaemia 
with haemoglobin < 6.5g/dl. The patients who were 
excluded: declined HIV test (30), had stigma about 
the disease (17), needed more counselling time (51), 
or tested positive for HIV ( 271) and referred to other 
centres offering government funded, free access to 
HAART, OI management drugs and other aspects 
of HIV care (Kenyatta National Hospital, Mission 
Hospitals, PGH Kisumu).
Figure 1 
Enrollment flow chart of the patients in the study
834 patients screened




354 patients referred 
to other centres for 
govt. funded HAART 
programmes
D.T.C done
370 excluded (incomplete data)
S6 East african MEdical Journal December 2013 (Supplement) 
Table 1
Patients recruitment during the study period.







2007   4
Total 464
Table 2
Baseline characteristics: Demographic and laboratory profile of the 464 study patients.
Characteristic Mean ± SD/Proportion
M:F ratio 256:208 (1.2:1)
Mean age (years) 37.2 ± 10.6 (12-78)
Mean CD4+ cell count (350-1600 cells/μl) 106.5 ± 125.2 (0.4-1022)





*CD4+ cell count clusters (350-1600cells/µl)
> 500  15 (3.2%)
350-499  19 (4.1%)
200-349 43 (9.3%)
< 200 387 (83.4%)
Haematology
Mean haemoglobin-(HB)-(10.6-17.0 g/dl) 7.16 ± 5.01 (2.9-13)
HB > 10.6 18 (3.9%)
HB 9.5-10.5 50 (10.8%)
HB 8.0-9.4 109 (23.5%)
HB 6.5-7.9 127 (27.3%)
HB< 6.5 160 (34.5%)
White blood cell count (4.8-10.8 X103/µl)
Mean white cell count 8.63 ± 8.8 (2.3-20.1 X 103/μl)
> 10.8 35 (7.5%)
4.8-10.8 191(41.2%)
< 4.8 238(51.3%)
Biochemistry (Mean ± SD)
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ALT (5-37 IU/L) 123.2 ± 20.1





HAART naïve ALL patients recruited
HAART regimen commenced None-354 (76.3%)*, triomune 30/40-60 (13.0%), 
Combivir/Efavirenz 34(7.3%),d4T/ddi/efavirenz 
16(3.4%)
*Reffered to other centres offering HAART
Data are Mean ± SD, or number of patients 
(%)
HAART
*CDC-Centres For Disease Control. Source, Morb. Mort. Week. Rep. 42 (No. RR-17), Dec. 18. 1992 
(A-asymptomatic PGL, B-Symptomatic, not A or C conditions, C-AIDS defining illness. HB-haemoglobin-
Anaemia classification, WHO/ACTG-anaemia grades REF: (20).  Combivir(AZT+3TC),ALT-alanine 
transaminase, AST-aspartate transaminase.
Figure 2
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Figure 3
Age group gender based distribution of patients with HIV who were seen at first presentation to the clinic
Table 3
Morbidity pattern and mode of diagnosis in cohort of the 464 HIV positive HAART naïve study patients.  
Disease/condition Freq. Mode of diagnosis
Herpes zoster virus (HZV) 21 Clinical
Tuberculosis (Pulmonary and 
extrapulmonary)
37 Sputum (Z-N staining), lymph node biopsy, chest 
x-ray
Cryptococcus Meningitis 124 CSF-Indian ink staining
Chronic Diarrhoea 
(cryptosporidium,giardia)
15 Stool-M/C/S, modified Z-N staining
Vasculitis 8 Clinical, venogram,C-T scan
Hepatitis B virus (HBV) 119 HBsAg  serology (ELISA method)
Oral Candidiasis 50 Clinical
Pneumocystis jiroveci pneumonia 
(PJP)
27 Clinical, LDH (lactate dehydrogenase), chest X-ray
Deep venous thrombosis-Lower 
limbs
5 Doppler ultrasound 
Cholecystitis/Cholangitis 78 Clinical, ultrasound of abdomen
Anaemia 396 Clinical, complete blood count
Pyomyositis 8 Surgical incision/drainage, pus culture,sensitivity.
Kaposi's Sarcoma 16 Biopsy and histology
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Sepsis * 5 Clinical, complete blood count. 
Bacterial Meningitis 8 CSF-M/C/S/biochemistry
Neuropathy 3 Clinical
Parotitis 3 Parotid gland biopsy and histology
Non Hodgkin’s lymphoma 14 Lymph node biopsy and histology
Toxoplasmosis 4 C-T scan head/brain, Toxoplasma antibodies
Psoriasis 4 Clinical
Hepatocellular carcinoma 12 Clinical,ultrasound,histology,α-fetoproteins
Sexually transmitted infections 10 Urine-M/C/S, clinical,pus swab-culture
Renal dysfunction 4 24 hour urinary protein,urea, electrolytes,creatinine
Sepsis-the patients had peritonitis, fallopian tube abscess, anal fissure, puerperal sepsis, and septic oral sores 
with attendant leucocytosis. It is noted that 248(53.6%) patients had two or more co-morbidities.
M/C/S - Microscopy, culture and sensitivity; CSF - Cerebrospinal fluid
Table 4
Demographic and laboratory profile of the patients who had > 2 co-morbidities.
Parameter Value
M:F 131: 117 (N=248)
Mean Age (years) 38.4 ± 11.5 (12-78)
CD4+ cell counts





Haemoglobin categories (normal-10.6-17 g/dl)
Mean haemoglobin 7.5 ± 3.13 (1-16.5)
> 10.6 None
9.5-10.5 70(28.3% ) patients
8- 9.4 31(12.5% ) patients
6.5- 7.9 40(16.1% ) patients
< 6.5 107(43.1% ) patients
Mean White blood cell count (X 109/L) 8.4 ± 4.97 (0.5-24.2)
Mean Neutrophil count(45-70%) 63.6 ± 18.4 (40-79.8)
Anaemia classification WHO/ACTG –anaemia grades REF (20).
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Table 5
Co-Morbidities.
Co-Morbodity No. of 
patients
Co-Morbidity No. of 
patients
Meninigitis/Sepsis 3 Cholecystitis/Kaposi's sarcoma 2






PJP/vasculitis/gastroenteritis 5 HBV/pneumonia 5
HBV/PJP/fallopian tubal abscess 1 HBV/Vasculitis 1
HBV/gastroenteritis 6 HBV/Hepatoma 4
DVT/pyomyoisitis 2 HBV/Oral candidiasis 7
Pyomyositis/Oral candidiasis 3
HBV/KS/Oral candidiasis 3 HBV/Genital ulcer disease 6
PTB/Oral candidiasis 5 HBV/meningitis-bacterial 2
PTB/cryptococcus HBV/Cholecystitis 1
Bacterial meningitis/gastroenteritis 4 H B V / C h o l e c y s t i t i s / O r a l 
candidiasis
1
PTB/PJP 2 HBV/Peritonitis 1
Pneumonia/Oral candidiasis 42 HBV/seborrhoea/PJP 1
Herpes zoster virus/Oral thrush 3 HBV/cryptococcus 1
PTB/HBV 9 Hepatoma/Oral candidiasis 1
PTB/AIDS dementia complex 1 HBV/Herpes zoster virus 1
PJP/HBV 2 HBV/Taenia corporis 5
Toxoplasmosis/cryptococcus 1 Non Hodgkin's lymphoma/oral 
thrush/pneumonia
3
PJP/Oral candidiasis 1 Hodgkin's lymphoma/ oral 
candidiasis/anaemia
10








Cholecytitis/Herpes zoster virus 
infection
11
HBV - Hepatitis B Virus
HCV - Hepatitis C Virus
KS - Keposi's Sarcoma
PJP - Pneumocycstis Jirovecic Pneumonia
PCB - Pulmonary Tuberculosis
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Figure 4
Distribution of CD4  count at presentation among 248 HIV positive patients seen in the medical outpatient clinic
Figure 5
Distribution of haemoglobin (HB) levels among 248 HIV positive patients seen at the medical outpatient clinics
DISCUSSION
HIV remains a major health burden in the third world, 
more so, the sub-Saharan Africa, that has the highest 
burden of the disease (5). HAART is proven to lead to 
suppression of HIV viral load to undetectable levels 
(<50 copies/μl), an increase in CD4+ cell count and a 
dramatic decrease of opportunistic infections (5).
 As depicted in the study, patients presented late 
to the various clinics with severe immunosuppression 
with a mean CD4+ cell count of 106.5 ± 125.2 cells/μl. 
Indeed, more than four out of five (83.4%) the study 
patients had CD4+ cell counts < 200 cells/μl, hence 
had severe immunosuppression. These patients had 
multiple co-morbidities where more than half 248 
(53.6%) had ≥2 co-morbidities. These patients required 
immediate treatment for opportunistic diseases/ co-
morbid conditions and HAART initiation to avert 
further clinical deterioration. Progress in effecting 
earlier diagnosis and initiating HAART remains 
an important public health goal but has been 
insufficient globally (6-8). In this Cohort, only 34(7.3%) 
patients had CD4+ cell counts > 350 cells/μl (the 
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The majority 430 (92.7%) patients had CD4+ cell 
counts < 350 cells/μl. These were patients with 
multiple co-morbidities, Table 5.
 Most opportunistic infections occur at lower 
CD4+ cell counts, < 350 cells/μl but we must remain 
cognisant of the fact that opportunistic infections 
also occur at higher CD4+ cell counts because of 
qualitative dysfunction and must be looked for 
and managed appropriately (9-11). Lately, Centres 
for Disease Control (CDC) has recommended HIV 
screening and testing in routine clinical care between 
the ages 13-65 years, in a Diagnostic Testing and 
Counselling (DTC )strategy. This would facilitate 
early detection of HIV disease, initiation of ARTs and 
maintenance of immune function or achievement 
of immune preservation before patients deteriorate 
(6-11). The reality is that many individuals may 
harbour undiagnosed HIV infection for long. Indeed 
studies have shown that increased screening is 
highly cost-effective, leads to early diagnosis of HIV 
infection which benefits both the individual by timely 
HAART initiation and the public by decreased HIV 
transmission either through behavioural changes 
and/or ART therapy (10, 11). 
 Worth mentioning are AIDS- associated 
malignances and non- infectious conditions 
(Non- Hodgkin’s lymphoma, Kaposi’s sarcoma, 
Progressive multifocal leucoencephalopathy, 
hepatocellular carcinoma, cholangitis/cholecystitis, 
deep venous thrombosis) which are poorly managed 
because most comprehensive care clinics do not 
have adequate diagnostic capacity and expertise in 
treatment in many centres outside cities except a few 
selected centres locally in this country. The patients 
therefore are expected to purchase these expensive 
co-therapies even though ARTs are provided free of 
charge. More often than expected, patients with HIV/
AIDS who are allergic to sulphonamides and have 
toxoplasmosis are expected to buy the expensive 
alternative treatments. Studies have shown that 
appropriate combined cytotoxic therapy for Kaposi’s 
sarcoma and non-Hodgkin’s lymphoma and HAART 
leads to adequate disease remission (12).
 Suffice to note that pulmonary Kaposi's sarcoma, 
progressive multifocal leucoencephalopathy and 
some non- Hodgkin’s lymphomas remain an 
ominous diagnosis and difficult to treat even in the 
HAART era and have a median survival between 6-18 
months (12-14). HAART has been shown to reduce 
the rates of Kaposi’s sarcoma and non Hodgkin’s 
lymphoma and not other cancers (13, 14). Thus, such 
co-morbidities in the study patients should not be 
a condemnation to mortality if and when managed 
appropriately and timely. 
 Cryptococcus meningitis, a major killer in 
HIV/AIDS patients is a critical and challenging 
co-morbidity. While few HIV care clinics have the 
right antifungal medications especially fluconazole, 
they do not always have amphotericin B and other 
alternatives for reasons of cost and expertise and 
facilities to monitor treatment. 
 P n e u m o c y s t i s  J i ro v e c i  p n e u m o n i a , 
toxoplasmosis, deep venous thrombosis, vasculitis 
and cholangitis/cholecystitis receive neither 
adequate diagnostic work up nor optimal therapy 
in the majority of patients because the cost is beyond 
reach of many of the patients like those included in 
this study. 
 In advanced HIV/AIDS disease, like the study 
patients in our cohort, protein S and factor VIII 
become progressively abnormal and are associated 
with vascular morbidities. Rising HIV- I viral load 
and declining CD4+ cell counts lead to increased 
factor VIII and decreased protein S activity leading 
to a hypercoagulable state (15). Therefore, it is 
not surprising that DVT occurs more frequently 
in the HIV-infected people than the un-infected 
population. 
 In the developed world, liver diseases are 
leading causes of non-AIDS deaths in HIV positive 
patients. 
 The risk factors for liver-related deaths in HIV 
positive patients include lower CD4+ cell count, 
hepatitis C virus (HCV) infection, active hepatitis B 
virus (HBV) infection, intravenous drug abuse and 
older age (16). HBV/HIV and HCV/HIV co-infections 
have been demonstrated in the local population 
(17, 18). The HIV care clinics must evaluate liver 
conditions and offer appropriate management in view 
of the prolonged life HIV patients anticipate while 
on HAART and the prevalence  of HBV infection in 
Kenya. Indeed, ARTs and certain co-medications for 
example,  anti-tuberculosis drugs, enhance the risk for 
liver damage. Tuberculosis is very common in HIV 
infected patients with severe immunosuppresion. 
Tuberculosis, both pulmonary and extra pulmonary 
Tuberculosis (TB) is a prevalent opportunistic 
infection. T.B infection is associated with higher HIV 
viral load. There is growing evidence in new case-
control studies that aggressively treating both HIV 
and T.B is beneficial (19). Indeed T.B infection is a 
major cause of death in HIV-infected patients 
worldwide and there is need for prompt anti-retroviral 
therapy in HIV-infected patients diagnosed with TB 
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(20). This study presents the magnitude of challenge 
in treating TB in severely immunocompromised HIV 
infected patients, especially in public health settings 
which use nevirapine based HAART combinations.
Lately efavirenz has been made available in public 
health ART programe.
 The prevalence of anaemia in this cohort was 
high at 396(85.3 %) patients having haemoglobin level 
< 9.4 g/dl and 160 (35.3%) patients had haemoglobin 
< 6.5. g/dl. Only 22 (4.7%) patients had haemoglobin 
> 10.6 g/dl. Anaemia in HIV is a poor prognostic 
marker of disease progression or death, independent 
of CD4+ cell counts and HIV viral load (21). Anaemia 
also delays the initiation of HAART especially when 
use of AZT is intended as part of first line combination 
therapy. Anaemia also impacts negatively on the 
quality of life of patients. Moderate to severe forms 
of anaemia may require blood transfusion before 
HAART initiation to avoid delay of treatment. This 
is especially so when there is pancytopaenia at the 
time when the patient presents to the clinic. HAART is 
effective in reducing the risk of anaemia and enabling 
low haemoglobin to recover although clinical trials 
data indicate that differences in the effects of HAART 
on anaemia exists between AZT-and d4T- based 
regimens (21,22). 
 Prevention of anaemia in patients with HIV/
AIDS should be the mainstay of management. As 
studies have identified that patients with CD4+ cell 
counts < 200 cells/mm3 and opportunistic diseases 
are at an increased risk, intervention with HAART 
along current treatment guidelines, that is, HAART 
before CD4+ cells fall below 250 cells/mm3, should 
reduce the risk of an individual developing anaemia 
(23). 
 A study in Spain demonstrated that earlier 
HAART initiation may reduce risk of progression 
of HIV infection to AIDS and that the best time to 
initiate HAART in asymptomatic HIV- infected 
patients appears to be before CD4+ cell counts falls 
below 350 cells/μl (23). Indeed, the HAART drugs are 
now better and there are more comfortable treatment 
regimens. 
 Over half, 238(51.3 %) patients had leucopaenia of 
< 4.8 × 103cml (4.8-10.3 × 103/ml), with an associated 
neutropaenia and lymphocytopaenia. It has been 
noted that worsening parameters of HIV/AIDS 
disease (low CD4+ cell count, high HIV viral load and 
presence of opportunistic infections) are associated 
with increasing occurrence of neutropaenia and more 
severe bacterial infections especially in women (21,22). 
A CD4+ cell count of < 200 cells/μl is associated with 
the increased risk of neutropaenia by 82% and an 
HIV-RNA load of >100,000 copies/ml increases the 
risk by 47% (22). However, in this study, HIV viral 
loads were not done because of high cost. CD4+ cell 
count and HIV- RNA are significant independent risk 
factors for developing neutropaenia. 
 HAART without zidovudine has been noted 
to significantly decrease the risk of developing 
neutropaenia. Zidovudine is associated with the 
development of anaemia and neutropaenia (22, 24).
 CD4+ cell counts do not rigidly define 
susceptibility to an opportunistic infection. Rather, 
there is a continuum of risk that decreases as the 
CD4+ cell count increases: the published thresholds 
are merely guidelines to direct clinicians. In the 
studies done, allowing the CD4+ cell count to fall to 
250 cells/μl permitted some of the patients to fall too 
far into the susceptible range and some may have 
had high viral loads to reduce immunologic function 
further (24). The traditional thresholds of CD4+ cell 
counts remain valuable, reliable indicators, but they 
represent a biologic spectrum of risk, not an absolute 
indicator. Thus, opportunistic infections can occur 
after initiation of HAART, but they usually occur when 
CD4+ cell counts are still low or they occur rarely at 
a “ higher than expected” CD4+ cell counts (25).   
In conclusion, many patients with HIV infection 
presented in advanced stage of the disease, severely 
immune-suppressed with opportunistic infections 
and several other co-morbidities. Two hundred and 
seventeen (87.5%) of the patients who had ≥ 2 co-
morbidities had CD4+ cell counts < 200 cells/μl. They 
received inadequate diagnostic work-up and access 
to comprehensive therapy because of cost. These 
issues complicate access to HAART and jeopardise 
patient outcomes in spite of the genuine efforts. We 
recognise that the exhaustive patient work- up was 
curtailed by costs and the opportunistic infections and 
co-morbidities may have been under-diagnosed or not 
fully defined. Severe HIV disease will therefore remain 
a major challenge to public health interventions of 
HIV management in resource-constrained settings for 
some time to come. Even when one accesses HAART, 
the severe opportunistic infections and severe co-
morbidities of HIV infections increases mortality 
escpecially when not correctly identified
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